人乳头瘤病毒治疗型疫苗的研究进展  

Progress in Study on Therapeutic Human Papillomavirus Vaccine

作　　者：王烨涛[1] 王国治[2] 姜典财[2] 

机构地区：[1]昆明理工大学生物工程技术研究中心,昆明650224 [2]中国药品生物制品检定所菌苗室,北京100050

出　　处：《中国生物制品学杂志》2009年第2期192-195,共4页Chinese Journal of Biologicals

摘　　要：人乳头瘤病毒(HPV)感染是导致尖锐湿疣的主要原因,约有90%的生殖器疣由HPV6、11型引起。我国妇女宫颈癌组织中HPV感染率大于95%,其中HPV16、18型占90%以上。随着对HPV及其致病机理研究的深入和免疫学的发展,利用免疫学方法治疗HPV引发的疾病显示出极大的应用前景。本文就人乳头瘤病毒治疗型疫苗的研究进展作一综述。Human papillomavirus（HPV ） is a major cause of condyloma acuminate. About 90% of genital warts are caused by infections with HPV6 and HPV 11. In China, the HPV infection rate in cervical cancer tissue was more than 95%, of which more than 90% was caused by HPV16 and HPV18. Along with the development of immunology as well as study on HPV and its pathogenic mechanism, the treatment of HPV-related diseases by immunological method is of excellent prospect. The progress in study on therapeutic HPV vaccine is reviewed in this paper.

关 键 词：人乳头瘤病毒 治疗型疫苗 细胞免疫 细胞毒性T淋巴细胞 

分 类 号：R737.33[医药卫生—肿瘤]